High-dose Norepinephrine Treatment

 November 10

by Jonathan Downham

In conclusion, high 28-day mortality of critically ill patients with shock who received high-dose norepinephrine in the ICU does not seem to be associated with underlying disease and comorbid conditions, the cause of shock, or dose or duration of norepinephrine treatment. However, our data suggest that treatment with norepinephrine is futile in patients with high disease severity, metabolic acidemia, and need for cotreatment with high doses of epinephrine. Our results may be helpful in future end-of-life decisions, at least in our ICU..link here

share this

Related Posts

Decompensated Alcohol Related Liver Disease Part 2

We return to our 48-year-old patient: jaundiced, hypotensive, drowsy, and bleeding. In decompensated cirrhosis, every treatment targets a disrupted system — splanchnic vasodilation, portal hypertension, toxin accumulation, and renal hypoperfusion.Although these patients look fluid overloaded, they are effectively hypovolaemic. Start with small aliquots of balanced crystalloid, avoiding 0.9% saline. In hepatorenal syndrome or tense ascites, 20% albumin is

Read More

Decompensated Alcohol Related Liver Disease

In this episode, I walk through the real-world critical care management of acute decompensated alcohol-related liver disease, using a high-risk ICU case to anchor the discussion. The focus is on understanding the underlying physiology—portal hypertension, rebalanced haemostasis, hepatic encephalopathy, infection, and hepatorenal syndrome—and translating that physiology into clear first-hour priorities at the bedside.  Listeners are

Read More